During ASCO, new data was presented from the “CARMENA” trial showing that overall survival for metastatic patients was not improved by performing a nephrectomy (or removing the primary tumor). This is a controversial question and one that is being debated by many physicians. We want to include the patient voice in that debate. Please take a few minutes to fill out this brief survey to help us sharing the patient perspective at ASCO. As always, your personal data will not be sharing with anyone. Thank you for taking part!